ClinicalTrials.gg
CompletedNCT06994832Updated Sep 24, 2026Results posted

Using Visual Arrays to Support Understanding of Genetic Risk

An interventional study of Visual Array and Narrative Visual Array in Decision Aid, sponsored by Stephanie B. Seminara, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Stephanie B. Seminara, MD · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,045
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States — 21 open to participants now, 33 under way, 2 of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · United States.

Enrollment
7th of 43
1,045 · median 162
Started
2025
with 4 others
No phase
28 of 72
9 open now
Registered
64th of 72
by date

Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, this one is the 7th largest by enrollment of the 43 interventional ones that give a count, is one of 5 that started in 2025, is one of 28 with no phase, and was the 64th registered.

Colorectal Neoplasms, Hereditary Nonpolyposis

147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 61 are open to participants now.

Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →

Open to participants now

21 of the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. The investigators also want to understand how people relate risk to their health. The main questions the study aims to answer are:

  1. Which visual aid most accurately show genetic risk?
  2. How do people perceive risk related to genetic test results?
  3. What factors are associated with people discussing their results with family?

Participants will:

  1. receive of of two visual aids showing risk
  2. state their estimation of risk
  3. answer questions about how they feel about risk and sharing information with family
Read the detailed description

This study aims to determine what visual aid helps people most accurately interpret risk from genetic test results. The study also examines how people perceive risk using the Tripartite Risk Model. Last, the study examines factors that are associated with intention to share genetic test results with family members.

Participants will provide brief sociodemographic information, complete brief health literacy and numeracy assessments, and questions about how they perceive risk. Participants will be informed of a genetic testing scenario and will receive one of two visual aids. After reviewing the visual aid, participants will state the risk shown in the visual aid and will answer questions about their perceived risk and sharing results with family members (blood relatives).

03

Conditions studied

  • Decision Aid

Keywords

  • Lynch syndrome
  • colorectal cancer
  • colon cancer
  • genetic testing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ability to read and understand English
  • opt-in consent

Exclusion criteria

Exclusion Criteria:

  • incorrect responses to validation questions
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,045 participants (actual)

Study arms

  • Experimental
    Visual Array & Choice

    Single, side-by-side visual array and non-directive decision frame

    Behavioral: Visual Array · Behavioral: Choice

  • Experimental
    Visual Array and Enhanced Choice

    Single, side-by-side visual array and decision frame with subjective norms nudge

    Behavioral: Visual Array · Behavioral: Enhanced Choice

  • Experimental
    Narrative Visual Array and Choice

    Evolving narrative showing sequential visual arrays and non-directive decision frame

    Behavioral: Narrative Visual Array · Behavioral: Choice

  • Experimental
    Narrative Visual Array and Enhanced Choice

    Evolving narrative showing sequential visual arrays and decision frame with subjective norms nudge

    Behavioral: Narrative Visual Array · Behavioral: Enhanced Choice

Interventions

  • BehavioralVisual Array

    Single side-by-side visual array

  • BehavioralNarrative Visual Array

    Evolving narrative with sequential visual arrays

  • BehavioralChoice

    Non-directive decision frame

  • BehavioralEnhanced Choice

    Decision frame with subjective norms nudge

06

What researchers measure

Primary outcomes

  1. Perceived Overall Accuracy of General Population Risk for Colorectal Cancer Prior to Seeing Array

    Differences between closest approximation to risk percentage depicted in the visual array that depicted risk with Lynch Syndrome (LS) minus risk without LS

    Time frame: immediately after the intervention

Secondary outcomes

  1. Accuracy of Risk for Colorectal Cancer for Someone Without Lynch Syndrome (Without Gene Mutation) From the Array

    Percent (%) estimated colorectal cancer risk for people like the general population. Closest approximation to risk percentage depicted in the visual array.

    Time frame: immediately after the intervention

  2. Accuracy of Risk for Colorectal Cancer for Someone With Lynch Syndrome From the Array

    Percent (%) estimated colorectal cancer risk for people with Lynch Syndrome. Closest approximation to risk percentage depicted in the visual array showing the population of people with Lynch Syndrome

    Time frame: immediately after the intervention

  3. Risk Perceptions - Percent

    Percent (%) estimated own lifetime risk for getting colorectal cancer. Perceptions of deliberative risk using 0-100 scale.

    Time frame: baseline

  4. Risk Perceptions - 7-point Likert-type Scale

    Perceptions of affective and experiential risk using 7-point Likert-type scales 1. Strongly agree 2. Agree 3. Somewhat agree 4. Neither agree nor disagree 5. Somewhat disagree 6. Disagree 7. Strongly disagree Higher scores indicate greater affective and experiential perceived personal colorectal cancer risk.

    Time frame: baseline

  5. Communication Intent

    Intent to communicate risk to blood relatives using 7-point Likert-type scale 1. Extremely unlikely 2. Unlikely 3. Somewhat unlikely 4. Neutral 5. Somewhat likely 6. Likely 7. Extremely likely Higher scores indicate greater expressed likelihood of communicating genetic risk to family members.

    Time frame: immediately after the intervention

07

Results

Posted Sep 24, 2026

Participant flow

Online only recruitment and participation. All recruitment and participation occurred between 28 July and 18 August 2025.

Array
Participant flow — Array
MilestoneVisual Array and ChoiceVisual Array and Enhanced ChoiceNarrative Visual Array and ChoiceNarrative Visual Array and Enhanced Choice
Started276257256252
Completed266249244242
Not completed1081210
Withdrew: Withdrawal by subject1081210
Family Communication
Participant flow — Family Communication
MilestoneVisual Array and ChoiceVisual Array and Enhanced ChoiceNarrative Visual Array and ChoiceNarrative Visual Array and Enhanced Choice
Started276257256252
Completed266249244242
Not completed1081210
Withdrew: Withdrawal by subject1081210

Outcome measures

PrimaryPerceived Overall Accuracy of General Population Risk for Colorectal Cancer Prior to Seeing Array

Differences between closest approximation to risk percentage depicted in the visual array that depicted risk with Lynch Syndrome (LS) minus risk without LS

Time frame:
immediately after the intervention
Reported as:
Mean · Percent (%)
Perceived Overall Accuracy of General Population Risk for Colorectal Cancer Prior to Seeing Array
Percent (%)Visual ArrayNarrative Visual Array
Perceived Overall Accuracy of General Population Risk for Colorectal Cancer Prior to Seeing Array13.65 ± 26.4311.11 ± 25.16
SecondaryAccuracy of Risk for Colorectal Cancer for Someone Without Lynch Syndrome (Without Gene Mutation) From the Array

Percent (%) estimated colorectal cancer risk for people like the general population. Closest approximation to risk percentage depicted in the visual array.

Time frame:
immediately after the intervention
Reported as:
Mean · Percent (%)
Accuracy of Risk for Colorectal Cancer for Someone Without Lynch Syndrome (Without Gene Mutation) From the Array
Percent (%)Visual ArrayNarrative Visual Array
Accuracy of Risk for Colorectal Cancer for Someone Without Lynch Syndrome (Without Gene Mutation) From the Array46.17 ± 27.9949.7 ± 27.92
SecondaryAccuracy of Risk for Colorectal Cancer for Someone With Lynch Syndrome From the Array

Percent (%) estimated colorectal cancer risk for people with Lynch Syndrome. Closest approximation to risk percentage depicted in the visual array showing the population of people with Lynch Syndrome

Time frame:
immediately after the intervention
Reported as:
Mean · Percent (%)
Accuracy of Risk for Colorectal Cancer for Someone With Lynch Syndrome From the Array
Percent (%)Visual ArrayNarrative Visual Array
Accuracy of Risk for Colorectal Cancer for Someone With Lynch Syndrome From the Array60.36 ± 15.8660.91 ± 15.73
SecondaryRisk Perceptions - Percent

Percent (%) estimated own lifetime risk for getting colorectal cancer. Perceptions of deliberative risk using 0-100 scale.

Time frame:
baseline
Reported as:
Mean · Percent (%)
Risk Perceptions - Percent
Percent (%)Visual ArrayNarrative Visual Array
Risk Perceptions - Percent3.38 ± 1.733.37 ± 1.76
SecondaryRisk Perceptions - 7-point Likert-type Scale

Perceptions of affective and experiential risk using 7-point Likert-type scales 1. Strongly agree 2. Agree 3. Somewhat agree 4. Neither agree nor disagree 5. Somewhat disagree 6. Disagree 7. Strongly disagree Higher scores indicate greater affective and experiential perceived personal colorectal cancer risk.

Time frame:
baseline
Reported as:
Mean · 7-point Likert-type scale score
Risk Perceptions - 7-point Likert-type Scale
7-point Likert-type scale scoreVisual ArrayNarrative Visual Array
Risk Perceptions - 7-point Likert-type Scale3.85 ± 0.573.86 ± 0.66
SecondaryCommunication Intent

Intent to communicate risk to blood relatives using 7-point Likert-type scale 1. Extremely unlikely 2. Unlikely 3. Somewhat unlikely 4. Neutral 5. Somewhat likely 6. Likely 7. Extremely likely Higher scores indicate greater expressed likelihood of communicating genetic risk to family members.

Time frame:
immediately after the intervention
Reported as:
Mean · 7-point Likert-type scale score
Communication Intent
7-point Likert-type scale scoreVisual Array and ChoiceNarrative Visual Array and ChoiceVisual Array and Enhanced ChoiceNarrative Visual Array and Enhanced Choice
Communication Intent5.14 ± 1.325 ± 1.465.14 ± 1.325 ± 1.46

Adverse events

Collected over Adverse events were collected from the time the participant began the study until completion of the survey - on average 12 minutes.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Visual Array and Choice0/276 (0%)0/276 (0%)0/276 (0%)
Visual Array and Enhanced Choice0/257 (0%)0/257 (0%)0/257 (0%)
Narrative Visual Array and Choice0/256 (0%)0/256 (0%)0/256 (0%)
Narrative Visual Array and Enhanced Choice0/252 (0%)0/252 (0%)0/252 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Year)Visual ArrayNarrative Visual ArrayTotal
Mean29.39 ± 2.741.99 ± 9.6535.54 ± 9.43
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Visual ArrayNarrative Visual ArrayTotal
Female161173334
Male367328695
Unknown (Not reported)5712
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Visual ArrayNarrative Visual ArrayTotal
American Indian or Alaska Native01010
Asian261339
Native Hawaiian or Other Pacific Islander101
Black or African American141428
White475458933
More than one race044
Unknown or Not Reported17926
08

Study locations

1 site
  • Boston College
    Boston, Massachusetts 02467, United States
09

References and documents

Publications

  • Keels JN, Babicheva V, McDonald IR, Witt JK, Dwyer AA. Optimizing Risk Communication for Lynch Syndrome: Results of a Randomized Controlled Trial of Visual Arrays for Genetic Testing. Cancers (Basel). 2026 Apr 25;18(9):1369. doi: 10.3390/cancers18091369. PubMed 42122165 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized data will be shared via the HarvardDataverse platform.

Time frame: Start date: within one month of the publication of study results. End date: one year after posting.

Access criteria: HarvardDataverse platform

Data sharing details ↗ · dataverse.harvard.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Aug 2025, 0 months.

Results were first posted in Sep 2026, 1 year 1 month after primary completion.

Of 37 interventional studies with no phase under Colorectal Neoplasms, Hereditary Nonpolyposis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 86. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
May 29, 2025
StartActual
Jul 28, 2025
Primary completionActual
Aug 18, 2025
CompletionActual
Aug 18, 2025
Results first posted
Sep 24, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06994832
Lead sponsor
Stephanie B. Seminara, MD
Responsible party
Stephanie B. Seminara, MD (Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine, Massachusetts General Hospital) — Sponsor-investigator
First posted
May 29, 2025
Start date
Jul 28, 2025
Primary completion
Aug 18, 2025
Completion
Aug 18, 2025
Results posted
Sep 24, 2026
Last update
Sep 24, 2026

Study contacts

Andrew A Dwyer, PhD
principal investigator · Boston College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion